There are many studies going on looking at the side effects of medications for every disease state. Most of these occur after the drugs are on the market and more people are using them.
One of the problems that can occur in these postmarking studies is the lack of good controls and patient choices. This means that a lot of great drugs can get a bum rap because of external influences.
The SGLT-2 Inhibitor class is no exception and this month’s special edition looks at what top thought leaders have to say about some of the recent results and how they should affect your prescribing habits.
Sometimes these studies can find positive results as well. Check out our latest article on the effects of these drugs have on reducing cardiovascular death.
Your partner in diabetes care,